Vigne Jonathan, Hyafil Fabien
Department of Nuclear Medicine, CHU de Caen Normandie, Normandie University (UNICAEN), Caen, France -
INSERM U1148, Laboratory for Vascular Translational Science (LVTS), DHU FIRE, University of Paris, Paris, France -
Q J Nucl Med Mol Imaging. 2020 Mar;64(1):21-34. doi: 10.23736/S1824-4785.20.03231-8. Epub 2020 Feb 18.
The role of nuclear imaging in the characterization of high-risk atherosclerotic plaque is increasing thanks to its high sensitivity to detect radiopharmaceuticals signal in tissues. Currently, 2-deoxy-2-[18F]fluoro-D-glucose ([18F]FDG) is the most studied and widely used radiopharmaceutical for the molecular imaging of atherosclerotic plaques with positron emission tomography (PET). [18F]FDG PET is a valuable tool to non-invasively detect, monitor and quantify inflammatory processes occurring in atherosclerotic plaques. The aim of this review is to gather insights provided by [18F]FDG PET to better understand the role of inflammation in the definitions of the vulnerable plaque and the vulnerable patient. Alternatives radiopharmaceuticals targeting inflammation and other potential high-risk plaque related processed are also discussed.
由于核成像对检测组织中的放射性药物信号具有高灵敏度，其在高危动脉粥样硬化斑块特征描述中的作用日益增强。目前，2-脱氧-2-[18F]氟-D-葡萄糖（[18F]FDG）是用于动脉粥样硬化斑块分子成像的正电子发射断层扫描（PET）中研究最多且应用最广泛的放射性药物。[18F]FDG PET是一种用于非侵入性检测、监测和量化动脉粥样硬化斑块中发生的炎症过程的有价值工具。本综述的目的是收集[18F]FDG PET提供的见解，以更好地理解炎症在易损斑块和易损患者定义中的作用。还讨论了针对炎症和其他潜在高危斑块相关过程的替代放射性药物。
